New Releases from NCBI BookshelfSotatercept (Winrevair): Indication: In combination with standard pulmonary arterial hypertension (PAH) therapy, for the treatment of adults with World Health Organization Group 1 PAH and Functional Class II or III: Reimbursement Recommendation [Internet].​Sotatercept (Winrevair): Indication: In combination with standard pulmonary arterial hypertension (PAH) therapy, for the treatment of adults with World Health Organization Group 1 PAH and Functional Class II or III: Reimbursement Recommendation [Internet].

By /

Canada’s Drug Agency (CDA-AMC) recommends that sotatercept (Winrevair) should be reimbursed by public drug plans for the treatment of patients with WHO Group 1 pulmonary arterial hypertension (PAH) if certain conditions are met.

​ 

Leave a Comment

Your email address will not be published. Required fields are marked *

Useful Links

NEWREDMARS SKILL AND RESEARCH        FOUNDATION

Registration No: 771800548      Contact Number : +91-8249516996

©2021-2024. Newredmars Skill and Research Foundation. All Rights Reserved.

Scroll to Top